Enliven Therapeutics (NASDAQ:ELVN) Given New $73.00 Price Target at Mizuho

Key Points

• Mizuho raised Enliven Therapeutics’ price target to $73 from $62 and maintained an “outperform” rating, implying 22.63% potential upside. Analysts overall assign the stock a “Moderate Buy” rating with an average target of $74.50.
• Shares opened at $59.53 and have risen significantly from their 12-month low of $14.78, while the company reported a quarterly loss of $0.49 per share—$0.10 worse than consensus expectations.
• Insiders sold 190,831 shares worth approximately $11 million over the past 90 days, although institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its price target increased by equities research analysts at Mizuho from $62.00 to $73.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Mizuho's price target would suggest a potential upside of 22.63% from the company's current price.

ELVN has been the subject of a number of other reports. HC Wainwright upped their price objective on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Thursday, July 9th. JonesTrading raised their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a "buy" rating in a report on Monday, June 29th. The Goldman Sachs Group upped their price target on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, Wall Street Zen lowered Enliven Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Enliven Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $74.50.

Enliven Therapeutics Stock Up 1.2%

NASDAQ ELVN opened at $59.53 on Tuesday. The stock has a market capitalization of $4.36 billion, a PE ratio of -35.65 and a beta of 0.27. The company has a 50 day moving average price of $51.42 and a two-hundred day moving average price of $41.13. Enliven Therapeutics has a 12-month low of $14.78 and a 12-month high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts anticipate that Enliven Therapeutics will post -1.67 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the transaction, the chief financial officer directly owned 46,054 shares of the company's stock, valued at $2,424,282.56. The trade was a 11.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 190,831 shares of company stock worth $10,991,723. Company insiders own 3.00% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds have recently modified their holdings of the business. KBC Group NV acquired a new stake in shares of Enliven Therapeutics in the first quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC bought a new stake in Enliven Therapeutics in the 4th quarter valued at $83,000. Finally, Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source